論文の公開元へ

書き出し

Refer/BibIX

RIS

BibTeX

TSV

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

Kamimura, Aya Miki, Akiko Kishi, Maya Okuda, Mina Hayashida-Hirano, Mayuka Sakamoto, Mari Matsumiya, Wataru Imai, Hisanori Kusuhara, Sentaro Nakamura, Makoto 神戸大学

2023.05.02

概要

Purpose: To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV). Methods: In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT. Results: A significant intergroup difference was noted in terms of age (P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P < 0.01). Conclusions: A htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods.

論文の公開元へ

この論文で使われている画像

参考文献

Hayashida M, Miki A, Nakai S, Matsumiya W, Imai H, Kusuhara S, et al. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy

with good baseline visual acuity. PLOS ONE. 2020; 15: e0240557. https://doi.org/10.1371/journal.

pone.0240557 PMID: 33044997

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy:

recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48: 82–118. https://

doi.org/10.1016/j.preteyeres.2015.05.003 PMID: 26026923

Tsai MJ, Hsieh YT. Half-time photodynamic therapy for central serous chorioretinopathy. Optom Vis

Sci. 2014; 91: 1140–1145. https://doi.org/10.1097/OPX.0000000000000360 PMID: 25083838

Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT. Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol. 2016; 167: 57–64. https://doi.org/10.1016/j.

ajo.2016.04.001 PMID: 27084002

Neves F, Costa J, Fonseca S, Silva L, Agrelos L. Half-dose photodynamic therapy for chronic central

serous chorioretinopathy: efficacy and safety outcomes in real world. Photodiagn Photodyn Ther. 2016;

14: 173–177. https://doi.org/10.1016/j.pdpdt.2016.04.012 PMID: 27126174

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, et al. One-year outcomes

with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2015; 122: 555–561. https://doi.org/10.1016/j.ophtha.2014.09.034 PMID: 25444637

van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF. Clinical characteristics of chronic central serous

chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.

Graefes Arch Clin Exp Ophthalmol. 2018; 256: 1395–1402. https://doi.org/10.1007/s00417-018-4003z PMID: 29732468

Hayashida M, Miki A, Honda S, Nakamura M. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central

serous chorioretinopathy. Photodiagn Photodyn Ther. 2020; 31: 101955. https://doi.org/10.1016/j.

pdpdt.2020.101955 PMID: 32818640

Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, et al. A multicenter study on the longterm outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J

Ophthalmol. 2016; 170: 91–99. https://doi.org/10.1016/j.ajo.2016.07.026 PMID: 27519561

10.

Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H. Long-term prognostic factors of chronic central

serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. PLOS ONE.

2017; 12: e0181479. https://doi.org/10.1371/journal.pone.0181479 PMID: 28742138

11.

Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central

serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina.

2012; 32: 1829–1837. https://doi.org/10.1097/IAE.0b013e3182680a66 PMID: 22850219

12.

Shiragami C, Takasago Y, Osaka R, Kobayashi M, Ono A, Yamashita A, et al. Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization. Am J Ophthalmol. 2018; 193:

80–86. https://doi.org/10.1016/j.ajo.2018.06.009 PMID: 29940168

13.

Sulzbacher F, Schu¨tze C, Burgmu¨ller M, Ve´csei-Marlovits PV, Weingessel B. Clinical evaluation of

neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by

swept source optical coherence tomography angiography (SS octa). Graefes Arch Clin Exp Ophthalmol. 2019; 257: 1581–1590. https://doi.org/10.1007/s00417-019-04297-z PMID: 31037488

PLOS ONE | https://doi.org/10.1371/journal.pone.0284979 May 2, 2023

9 / 10

PLOS ONE

Treatment outcome of half-time PDT for chronic CSC with and without CNV

14.

Zhou X, Komuku Y, Araki T, Terasaki H, Miki A, Kuwayama S, et al. Risk factors and characteristics of

central serous chorioretinopathy with later development of macular neovascularisation detected on

OCT angiography: a retrospective multicentre observational study. BMJ Open Ophthalmol. 2022; 7.

https://doi.org/10.1136/bmjophth-2022-000976 PMID: 35537029

15.

Hwang S, Noh H, Kang SW, Kang MC, Lee D, Kim SJ. Choroidal neovascularization secondary to

photodynamic therapy for central serous chorioretinopathy: Incidence, Risk Factors, and Clinical

Outcomes. Retina. 2021; 41: 1762–1770. https://doi.org/10.1097/IAE.0000000000003067 PMID:

33315827

16.

Yang C, Chen K, Lee S, Lee F. Photodynamic therapy in the treatment of choroidal neovascularization

complicating central serous chorioretinopathy. J Chin Med Assoc. 2009; 72: 501–505. https://doi.org/

10.1016/S1726-4901(09)70417-4 PMID: 19762322

17.

Ergun E, Tittl M, Stur M. Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol. 2004; 122: 37–41. https://doi.org/

10.1001/archopht.122.1.37 PMID: 14718292

18.

Chan WM, Lam DSC, Lai TYY, Yuen KSC, Liu DTL, Chan CKM, et al. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol. 2003; 136: 836–45. https://doi.org/10.1016/s0002-9394(03)00462-8 PMID: 14597034

19.

Hu YC, Chen YL, Chen YC, Chen SN. 3-year follow-up of half-dose verteporfin photodynamic therapy

for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci

Rep. 2021; 11: 13286. https://doi.org/10.1038/s41598-021-92693-z PMID: 34168238

20.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. HalfDose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in

Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018; 125:

1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021 PMID: 29776672

21.

Chubachi A, Miki A, Hayashida M, Sakamoto M, Imai H, Kusuhara S, et al. Clinical factors associated

with low-contrast visual acuity after reduced-fluence photodynamic therapy in patients with resolved

central serous chorioretinopathy and good baseline visual acuity. Pharmaceuticals (Basel). 2021; 14.

https://doi.org/10.3390/ph14040303 PMID: 33800693

22.

Chen YC, Chen SN. Three-year follow-up of choroidal neovascularisation in eyes of chronic central

serous chorioretinopathy. Br J Ophthalmol. 2020; 104: 1561–1566. https://doi.org/10.1136/

bjophthalmol-2019-315302 PMID: 32051140

23.

Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S, et al. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization

in chronic central serous chorioretinopathy. Eye (Lond). 2016; 30: 805–811. https://doi.org/10.1038/

eye.2016.41 PMID: 26965012

24.

Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, et al. Photodynamic therapy combined with

anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLOS ONE. 2021;

16: e0248760. https://doi.org/10.1371/journal.pone.0248760 PMID: 33755678

25.

Li M, Qu J, Liang Z, Tang J, Hu J, Yao Y, et al. Risk factors of persistent subretinal fluid after half-dose

photodynamic therapy for treatment-naïve central serous chorioretinopathy. Graefes Arch Clin Exp

Ophthalmol. 2022; 260: 2175–2182. https://doi.org/10.1007/s00417-021-05531-3 PMID: 35024912

26.

Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A. Optical coherence tomography

angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy.

Retina. 2018; 38: 629–638. https://doi.org/10.1097/IAE.0000000000001580 PMID: 28267114

PLOS ONE | https://doi.org/10.1371/journal.pone.0284979 May 2, 2023

10 / 10

...

参考文献をもっと見る

分野

大学

学位論文種類・取得年

言語

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

概要

この論文で使われている画像

関連論文

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.

Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Characteristics of pachychoroid neovasculopathy

参考文献

分野

大学

学位論文種類・取得年

言語

コピーが完了しました

URLをコピーしました

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

概要

この論文で使われている画像

関連論文

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.

Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Characteristics of pachychoroid neovasculopathy

参考文献